Executive Employment Agreement between Neumora Therapeutics, Inc. and Joshua Pinto, Ph.D.
This agreement is between Neumora Therapeutics, Inc. and Joshua Pinto, Ph.D., effective February 14, 2025. It outlines Dr. Pinto’s role as President, his duties, compensation (including a $645,000 annual salary, bonus eligibility, and a $970,000 signing bonus), and employment terms. The agreement requires Dr. Pinto to devote full time to the company, with certain exceptions, and details conditions for bonus payments and repayment if employment ends early. It replaces a prior agreement and sets the terms for Dr. Pinto’s continued employment.
Exhibit 10.18
NEUMORA THERAPEUTICS, INC.
EXECUTIVE EMPLOYMENT AGREEMENT
This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Joshua Pinto, Ph.D. (“Executive” and, together with the Company, the “Parties”) effective as of February 14, 2025 (the “Effective Date”). This Agreement supersedes in its entirety the Executive Employment Agreement between Executive and the Company dated as of April 11, 2022 (the “Prior Agreement”).
WHEREAS, the Company desires to assure itself of the continued services of Executive by engaging Executive to perform services as an employee of the Company under the terms hereof;
WHEREAS, Executive desires to provide continued services to the Company on the terms herein provided; and
WHEREAS, the Parties desire to execute this Agreement to supersede the Prior Agreement in its entirety effective as of the Effective Date.
NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, including the respective covenants and agreements set forth below, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:
2
Vacation. Executive will be entitled to paid vacation in accordance with the Company’s vacation policy, as in effect from time to time.
3
4
(B) The Company shall pay to Executive an amount equal to Executive’s Annual Bonus for the year of termination assuming achievement of all performance goals at target. Such amount will be subject
5
to applicable withholdings and payable in a single lump sum payment on the first regular payroll date following the date the Release becomes effective and irrevocable or as otherwise provided in Section 11(d) hereof.
During the period commencing on the Date of Termination and ending on the last day of the Severance Period, or if earlier, the date on which Executive becomes eligible for comparable replacement coverage under a subsequent employer’s group health plan (in any case, the “Non-CIC COBRA Period”), subject to Executive’s valid election to continue healthcare coverage under Section 4980B of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations thereunder, the Company shall, in its sole discretion, either (x) continue to provide to Executive and Executive’s dependents, at the Company’s sole expense, or (y) reimburse Executive and Executive’s dependents for coverage under its group health plan (if any) at the same levels in effect on the Date of Termination; provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the Non-CIC COBRA Period (or remaining portion thereof).
6
7
8
9
10
11
12
13
[Signature Page Follows]
14
IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the date and year first above written.
NEUMORA THERAPEUTICS, INC.
By: /s/ Amy Sullivan
Name: Amy Sullivan
Title: Chief Human Resources Officer
EXECUTIVE
By: /s/ Joshua Pinto
Name: Joshua Pinto, Ph.D.
Address:
Exhibit A
PERMITTED OUTSIDE ACTIVITIES
Exhibit B
FAILURE TO SUCCEED
For the purposes of Section 3(c) of the Agreement, “Failure to Succeed” shall mean the failure of Executive to be appointed as the successor CEO in the event that, after February 14, 2025, the employment of the CEO terminates for any reason.